|
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Clinical research trials and Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome clinical trial. Participants typically obtain the most effective healthcare available for their Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome  Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
For Condition: Acute Myeloid Leukemia,atypical chronic myeloid leukemia,adult acute monocytic leukemia,Chronic Myelomonocytic Leukemia,myelodysplastic and myeloproliferative disease
Status: Recruiting
Sponsor(s): Leukemia Research Fund ,
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known if stronger doses of chemotherapy given over a longer period of time are as well tolerated or as effective as less intensive chemotherapy. PURPOSE: Randomizedphase III trial to compare intensive with nonintensive regimens of chemotherapy in treating older patients who have acute myeloid leukemia or myelodysplastic syndrome.
Details: OBJECTIVES: - Compare the response rate, survival, quality of life, and supportive care requirements with intensive versus nonintensive chemotherapy in older patients with acute myeloid leukemia or high risk myelodysplastic syndrome. - Compare response achievement, response duration, survival, toxicity and supportive care requirements with differing doses of daunorubicin and cytarabine in these patients receiving intensive chemotherapy. - Determine the efficacy of PSC 833 in enhancing the effects of daunorubicin in these patients receiving intensive chemotherapy. - Compare relapse rate, deaths in complete remission, disease free survival, and survival with short versus long intensive chemotherapy in these patients. - Compare response achievement, response duration, survival, toxicity, quality of life, and resource use with hydroxyurea versus cytarabine in these patients receiving low dose chemotherapy. - Determine response achievement, response duration, survival, toxicity, quality of life, and supportive care requirements with the addition of tretinoin to the nonintensive chemotherapy in these patients. - Assess the correlation between P-gp and BCL-2 in family members and treatment outcomes and other prognostic factors in these patients with these treatment regimens. OUTLINE: This is a randomized study. Patients are randomized or electively assigned to either intensive or nonintensive chemotherapy. Intensive chemotherapy - Patients are randomized to 1 of 6 treatment arms. Patients receive 2 courses of chemotherapy comprising 1 of 2 daunorubicin doses, 1 of 2 cytarabine doses, thioguanine, and with or without PSC 833. Patients receive daunorubicin IV once daily on days 1-3 with cytarabine IV twice daily and oral thioguanine once daily on days 1-10 during course 1. Treatment repeats in approximately 31 days as in course 1 except cytarabine and thioguanine are given only on days 1-8. - Arm I: Patients receive higher dose of daunorubicin, lower dose of cytarabine, and thioguanine. - Arm II: Patients receive higher dose of daunorubicin, higher dose of cytarabine, and thioguanine. - Arm III: Patients receive lower dose of daunorubicin, lower dose of cytarabine, and thioguanine. - Arm IV: Patients receive lower dose of daunorubicin, higher dose of cytarabine, and thioguanine. - Arm V: Patients receive treatment as in arm III in combination with continuous infusion of PSC 833 beginning day 1. - Arm VI: Patients receive treatment as in arm IV in combination with continuous infusion of PSC 833 beginning on day 1. Patients with refractory disease after the first course of induction chemotherapy may continue with the intensive protocol arm or enter the nonintensive arm. Patients who do not achieve complete remission after completion of induction chemotherapy are removed from study. Patients in complete remission after induction therapy receive consolidation therapy. - Patients in complete remission after induction are randomized to either short or long consolidation. - Short consolidation: Patients receive mitoxantrone IV on days 1-3 and cytarabine IV over 2 hours twice daily on days 1-3. - Long consolidation: Patients complete short consolidation and then receive idarubicin IV over 5 minutes once daily on days 1 and 3, cytarabine IV over 2 hours twice daily and etoposide IV over 1 hour once daily on days 1-3. Non-intensive chemotherapy - Patients are randomized to 1 of 4 treatment arms. - Arm I: Patients receive oral hydroxyurea as necessary to control WBC count until treatment failure. - Arm II: Patients receive hydroxyurea as in arm I and oral tretinoin daily for up to 16 weeks. - Arm III: Patients receive low dose cytarabine subcutaneously twice daily on days 1-10 every 28 days for a minimum of 4 courses. - Arm IV: Patients receive cytarabine as in arm III plus oral tretinoin daily for up to 16 weeks. Quality of life is assessed at study entry, and then at 1, 3, and 6 months. Patients are followed at one year. PROJECTED ACCRUAL: Approximately 2,000 patients (1,200 to intensive arm and 800 to nonintensive arm) will be accrued for this study over 5 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 60 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Acute myeloid leukemia (de novo or secondary) OR - Myelodysplastic syndrome - More than 10% myeloblasts in the bone marrow - Refractory anemia with excess blasts - Refractory anemia with excess blasts in transformation - Chronic myelomonocytic leukemia - No promyelocytic leukemia (FAB type M3) - No blastic phase chronic myeloid leukemia PATIENT CHARACTERISTICS: Age: - 60 and over (younger patients allowed if intensive chemotherapy not indicated) Performance status: - Not specified Life expectancy: - Not specified Hematopoietic: - Not specified Hepatic: - Not specified Renal: - Not specified Cardiovascular: - No myocardial infarction within past 6 months in patients receiving daunorubicin or PSC 833 Other: - No other concurrent active malignancy PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior cytotoxic chemotherapy for leukemia Endocrine therapy: - Not specified Radiotherapy: - Not specified Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
AlanBurnett, Study Chair, University of Wales College of Medicine
University of Wales College of Medicine *Recruiting*
Cardiff, Wales, CF14 4XN
United Kingdom
Recruiting Alan Burnett 44-29-2074-2375
University College Hospital *Recruiting*
London, England, WC1E 6AU
United Kingdom
Recruiting Antony Goldstone 44-20-7380-9678
Queen Elizabeth Hospital at University of Birmingham *Recruiting*
Birmingham, England, B15 2RR
United Kingdom
Recruiting Keith Wheatley 44-121-472-1311
Additional Information:
Study ID Numbers: CDR0000067831; LRF-AML14,EU-20016
Study Start Date:
Record last reviewed: September 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005823
Other Myelodysplastic And Myeloproliferative Disease Studies:
1. Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML with PDGF-R Fusion Genes, or Mastocytosis with Gleevec
2. FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
3. Decitabine in Treating Patients With Myelodysplastic Syndrome
4. Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
5. Imatinib Mesylate in Treating Patients With Myelofibrosis
Related Studies:
Other myelodysplastic and myeloproliferative disease Clinical Trials
Other England Clinical Trials
Other Birmingham Clinical Trials
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
|
|
|
|
|
|
|
